NuCana (NASDAQ:NCNA) Sees Unusually-High Trading Volume

NuCana PLC (NASDAQ:NCNA) saw an uptick in trading volume on Tuesday . 845,116 shares changed hands during trading, an increase of 1,373% from the previous session’s volume of 57,379 shares.The stock last traded at $7.55 and had previously closed at $7.32.

Several research firms have weighed in on NCNA. BidaskClub raised shares of NuCana from a “strong sell” rating to a “sell” rating in a research report on Wednesday, July 31st. HC Wainwright began coverage on shares of NuCana in a research report on Monday. They set a “buy” rating and a $20.00 target price on the stock. William Blair reissued an “outperform” rating on shares of NuCana in a research report on Thursday, May 16th. ValuEngine raised shares of NuCana from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Zacks Investment Research downgraded shares of NuCana from a “buy” rating to a “hold” rating in a research report on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $22.33.

The firm’s fifty day moving average price is $9.06 and its 200 day moving average price is $12.46. The firm has a market capitalization of $235.89 million, a PE ratio of -12.81 and a beta of 3.27.

Hedge funds have recently added to or reduced their stakes in the company. Susquehanna International Group LLP bought a new stake in shares of NuCana during the second quarter worth $139,000. Tower Research Capital LLC TRC bought a new stake in shares of NuCana during the second quarter worth $32,000. BlackRock Inc. raised its position in shares of NuCana by 134,310.2% during the second quarter. BlackRock Inc. now owns 608,878 shares of the company’s stock worth $6,320,000 after acquiring an additional 608,425 shares during the last quarter. Asymmetry Capital Management L.P. raised its position in shares of NuCana by 257.8% during the second quarter. Asymmetry Capital Management L.P. now owns 162,414 shares of the company’s stock worth $1,686,000 after acquiring an additional 117,021 shares during the last quarter. Finally, Aperio Group LLC bought a new stake in shares of NuCana during the second quarter worth $39,000. 40.21% of the stock is currently owned by institutional investors and hedge funds.

NuCana Company Profile (NASDAQ:NCNA)

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary cancer; and Phase III clinical trials for the treatment of pancreatic cancer.

Featured Story: CD Ladder

Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.